{"id":"NCT00680225","sponsor":"New England Retina Associates","briefTitle":"Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma","officialTitle":"Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2012-07","completion":"2012-07","firstPosted":"2008-05-20","resultsPosted":"2017-04-12","lastUpdate":"2017-04-12"},"enrollment":10,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Choroidal Melanoma"],"interventions":[{"type":"DRUG","name":"Ranibizumab injection and TTT - ICG based","otherNames":["Lucentis injection"]}],"arms":[{"label":"Lucentis Injection","type":"EXPERIMENTAL"}],"summary":"To report preliminary results on safety and tolerability of intravitreal injection of Ranibizumab (Lucentis) combined with Transpupillary Thermotherapy (TTT)+ Indocyanine Green (ICG)-based photodynamic therapy (PDT) in the treatment of choroidal melanoma.","primaryOutcome":{"measure":"Mean Tumor Thickness","timeFrame":"12 mo","effectByArm":[{"arm":"Lucentis Injection","deltaMin":2.91,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":7,"exclusionCount":8},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":0},"commonTop":[]}}